Modeling of internal dose distributions during SR-89 treatment of a patient with bone metastases

Cancer Biotherapy and Radiopharmaceuticals

Volumn 12, Issue 5, 1997, Pages 355-362

  Bialkowski, Miroslaw M ^b   Wierzbicki, Jacek G ^a,c   Porter, Arthur T ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b Department of Medicine Rutgers Health Community Medical Center Internal Medicine Residency Program   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Biodistribution; Internal dosimetry; Metastases; Strontium 89

Indexed keywords

STRONTIUM 89;

ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; DOSE CALCULATION; HUMAN; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOISOTOPE THERAPY;

EID: 0031442958     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1997.12.355     Document Type: Article

References (28)

1. 89strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urol 1976;116:764-768.
2. Silberstein EB, Williams C. Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 1985;26:345-348.
3. Kloiber R, Molnar ChP, Barnes M. Sr-89 therapy for metastatic bone disease: scintigraphic and radiographic follow-up. Radiology 1987;163:719-723.
4. McEwan AJB, Porter AT, Venner PM, Amyotte G. An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy. Antibody, Immunoconjugates, and Radiopharmaceuticals 1990;3:91-98.
5. Laing AH, Ackery DM, Bayly, et al. Strontium chloride for pain palliation in prostatic skeletal malignancy. Brit J Radiol 1991;64:816-822.
6. Mertens WC, Porter AT, Reid RH, Powe JE. Strontium-89 and low dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: preliminary report. J Nucl Med 1992;33:1417-1443.
7. Porter AT, McEwan AJB. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Seminars in Oncology 1993;20:38-43.
8. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Rad Oncol Biol Phys 1993;25:805-813.
9. Dickinson Ch Z, Hendrix NS. Strontium-89 therapy in painful bony metastases. J Nucl Med Technol 1993;21:133-137.
10. Hansen DV, Holmes ER, Catton G, Thorne DA, Chadwick DH, Schmutz DA. Strontium-89 therapy for painful osseous metastatic prostate and breast cancer. Am. Family Physician 1993;47:1795-1800.
11. Robinson RH, Preston DF, Baxter KG, Dusing RW, Spicer JA. Clinical experience with strontium-89 in prostatic and breast cancer patients. Seminars in Oncology 1993;20:44-48.
12. Scher HI, Chung LWK. Bone metastases: improving the therapeutic index. Seminars in Oncology 1994;21:630-656.
13. ICRP Publication 30 Limits for Intakes of Radionuclides by Workers. 1978; Part 1: 12-22, 35-46, 56-62.
14. Leggett RW. A generic age-specific biokinetic model for calcium-like elements. Radiation Protection Dosimetry 1992;41:183-198.
15. Annals of the ICRP 1993;23:95-120.
16. Spencer H, Li M, Samachson J, Laszlo D. Metabolism of strontium-85 and calcium-45 in man. Meeting of the Federation of the American Society for Experimental Biology 1958; Philadelphia, PA.
17. McDonald NS, Figueroa WG, Urist MR. Short term retention of strontium-85 and estimation of initial strontium-90 burdens in humans. Health Physics 1965,11.1187-1194.
18. Harrison GE, Carr TEF, Sutton A Distribution of radioactive calcium, strontium, barium and radium following intravenous injection into a healthy man. Int J Radiat Biol 1967;13:235-247.
19. Bishop M, Harrison GE, Raymond WHA, Sutton A, Rundo J. Excretion and retention of radioactive strontium in normal men following a single intravenous injection. Int J Radiat Biol 1969;2:124-142.
20. Robinson RG, Blake GM, Preston DF, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989;9:271-281.
21. Newton D, Harrison GE, Rundo J, Kang C, Warner AJ. Metabolism of Ca and Sr in late adult life. Health Physics 1990;59.433-442.
22. Breen SL, Powe JE, Porter AT. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med 1992;33:1316-1323.
23. Ben-Josef E, Maughan RL, Vasan S, Porter AT. A direct measurement of strontium-89 activity in bone metastases. Nucl Med Comm 1995;16:452-456.
24. Ackery D, Yardley J. Radionuclide-targeted therapy for the management of metastatic bone pain. Seminars in Oncology 1993;20:27-31.
25. Mertens WC. Radionuclide therapy of bone metastases: prospects for enhancement of therapeutic efficacy. Seminars in Oncology 1993;20:49-55.
26. Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ, Ackery DM Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 1988;29:549-557.
27. Blake GM, Zivanovic MA, McEwan AJ, Condon RB, Ackery DM. Strontium-89 therapy, strontium kinetics and dosimetry in two patients treated for metastasizing osteosarcoma. Brit J Radiol 1987;60,:253-259.
28. Tennval J, Darte L, Lundgren R, Hassan AM. Palliation of multiple bone metastases from prostatic carcinoma with strontium-89. Acta Oncologica 1988,27:365-369.